A woman from Philadelphia has filed a Lipitor lawsuit that claims use of the popular statin drug caused her to develop Type 2 diabetes. The lawsuit, which was filed in U.S. District Court, Eastern District of Pennsylvania late last month, alleges that Pfizer failed to properly disclose the risks associated with Lipitor use.
The Pennsylvania complaint is just the most recent lawsuit filed in federal court to allege a connection between Lipitor and diabetes. Last month, the U.S. Judicial Panel on Multidistrict Litigation (JPML) declined a request by plaintiffs to consolidate all federally-filed Lipitor diabetes claims in a single federal jurisdiction for pretrial proceedings. At the time, only five Lipitor lawsuits were pending in U.S. federal courts, and the Panel held that this was too few to justify the establishment of a multidistrict litigation. The Panel also noted that Lipitor cases pending in South Carolina federal court are already being handled in a consolidated manner, and that Pfizer says it is “ready and willing to work with Plaintiffs’ counsel in the [non-South Carolina] actions to appropriately coordinate any common discovery or other pretrial matters across the cases.” As such, the JPML did not feel that the creation of a Lipitor multidistrict litigation was necessary at this time.
Lipitor is a statin, a class of cholesterol-lowering medications that were developed back in the mid-1990s. Before generic versions became available in 2011, Lipitor was the best selling drug in history, racking up sales in excess of $125 billion.
In 2012,the U.S. Food & Drug Administration (FDA) issued a Drug Safety Communication to inform the public about modifications to the Lipitor label that included information about the possible link between Lipitor and diabetes. Just before the alert was issued, a study published in the Archives of Internal Medicine reported that post-menopausal women who took drugs like Lipitor faced “a 48 percent increased risk of diabetes.” Just this past May, a British Medical Journal study found that Lipitor patients had a 22 percent higher risk of new-onset diabetes. However, despite the growing body of evidence linking use of this drug to Type 2 diabetes, the FDA has yet to issue a Lipitor recall.
Plaintiffs in Lipitor diabetes lawsuits claim that Pfizer was aware of the connection between Lipitor and diabetes prior to the 2012 label change, but continued to promote and market Lipitor as safe and effective. The lawsuits also assert that the 2012 label modifications did not go far enough, and claim that plaintiffs would have either chosen not to use Lipitor, or would have closely monitored their blood glucose level, had this risk been properly disclosed by Pfizer.
If you are concerned that taking Lipitor caused you to develop Type 2 diabetes, please contact Bernstein Liebhard LLP for a free Lipitor lawsuit review. Our attorneys have helped hundreds of people harmed by defective drugs obtain compensation for their injuries, and they will be able to determine if you have a valid claim. To learn more, please call .